CalciMedica (CALC) News Today → Charles Payne Demystifies Options (From Unstoppable Prosperity) (Ad) Free CALC Stock Alerts $5.43 -0.05 (-0.91%) (As of 05:17 PM ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 16 at 7:27 AM | marketbeat.comQ2 2024 EPS Estimates for CalciMedica, Inc. Boosted by Analyst (NASDAQ:CALC)CalciMedica, Inc. (NASDAQ:CALC - Free Report) - Research analysts at HC Wainwright lifted their Q2 2024 earnings per share (EPS) estimates for CalciMedica in a report released on Tuesday, May 14th. HC Wainwright analyst J. Pantginis now forecasts that the company will earn ($0.42) per share for tMay 15 at 6:22 AM | americanbankingnews.comCalciMedica (NASDAQ:CALC) Earns "Buy" Rating from HC WainwrightMay 14 at 9:16 PM | finanznachrichten.deCalciMedica, Inc.: CalciMedica Reports First Quarter 2024 Financial Results and Provides Clinical & Corporate UpdatesMay 14 at 9:16 PM | markets.businessinsider.comOptimistic Buy Rating for CalciMedica Backed by Strong Financials and Promising Clinical TrialsMay 14 at 8:19 AM | marketbeat.comHC Wainwright Reiterates Buy Rating for CalciMedica (NASDAQ:CALC)HC Wainwright restated a "buy" rating and set a $20.00 target price on shares of CalciMedica in a report on Tuesday.May 13 at 4:05 PM | prnewswire.comCalciMedica Reports First Quarter 2024 Financial Results and Provides Clinical & Corporate UpdatesMay 7, 2024 | prnewswire.comCalciMedica Announces Upcoming Presentation at Digestive Disease Week 2024April 29, 2024 | marketbeat.comCalciMedica, Inc. (NASDAQ:CALC) Short Interest UpdateCalciMedica, Inc. (NASDAQ:CALC - Get Free Report) was the recipient of a significant drop in short interest during the month of April. As of April 15th, there was short interest totalling 33,600 shares, a drop of 9.7% from the March 31st total of 37,200 shares. Based on an average daily trading volume, of 23,000 shares, the days-to-cover ratio is currently 1.5 days. Approximately 0.7% of the company's stock are short sold.April 24, 2024 | prnewswire.comCalciMedica Announces Last Patient Enrolled in Phase 2b CARPO Trial of Auxora™ in Acute PancreatitisApril 3, 2024 | msn.comCalciMedica And 2 Other Penny Stocks Insiders Are BuyingMarch 28, 2024 | finance.yahoo.comCalciMedica Reports 2023 Financial Results and Provides Clinical & Corporate UpdatesMarch 13, 2024 | prnewswire.comCalciMedica Presents Data from Preclinical Studies of Auxora in Acute Kidney Injury at the 29th International AKI & CRRT ConferenceFebruary 28, 2024 | finance.yahoo.comCalciMedica Announces Presentation of Data from a Preclinical Study of Auxora in Acute Kidney Injury at the 29th International AKI & CRRT ConferenceFebruary 24, 2024 | msn.comSeaStar’s device granted humanitarian exemption approval for children with AKIFebruary 24, 2024 | msn.comCalciMedica (CALC) Price Target Increased by 61.73% to 16.70February 20, 2024 | it.investing.comSingular Research alza il target del titolo CalciMedica a 9,50 dollari in presenza di un nuovo fondoFebruary 19, 2024 | ca.investing.comCalciMedica stock target raised to $9.50 by Singular Research amid new fundFebruary 16, 2024 | marketbeat.comTrading was temporarily halted for "CALC" at 09:02 AM with a stated reason of "LULD pause."February 14, 2024 | msn.comCalciMedica given FDA approval for Phase II trial of AuxoraFebruary 14, 2024 | markets.businessinsider.comCalciMedica’s Auxora Braces for Phase 2 Trial with Strong Buy Rating from Analyst Joseph PantginisFebruary 13, 2024 | markets.businessinsider.comCalciMedica Announces FDA Clearance Of IND Application For Phase 2 Trial Of AuxoraFebruary 7, 2024 | finance.yahoo.comCalciMedica to Present at the Oppenheimer 34th Annual Healthcare Life Sciences ConferenceFebruary 2, 2024 | marketbeat.comTrading was temporarily halted for "CALC" at 11:02 AM with a stated reason of "LULD pause."February 2, 2024 | marketbeat.comTrading was temporarily halted for "CALC" at 10:02 AM with a stated reason of "LULD pause."January 28, 2024 | msn.comHuge Insider Buys From Warren Buffett, Jack Ma, Carlos Slim and MoreJanuary 22, 2024 | markets.businessinsider.comCalciMedica Announces Private Offering For Up To About $55 Mln; Stock Down In Pre-marketJanuary 22, 2024 | marketwatch.comCalciMedica Shares Rally After Funding Lined Up for Lead Product CandidateJanuary 22, 2024 | finance.yahoo.comCalciMedica Announces Private Placement of up to Approximately $55 MillionDecember 11, 2023 | finance.yahoo.comCalciMedica Collaborator St. Jude Children's Research Hospital Presents Data from Initial Cohort of CRSPA Study at 65th Annual ASH Meeting & ExpositionNovember 9, 2023 | msn.comCalciMedica GAAP EPS of -$0.82November 9, 2023 | finance.yahoo.comCalciMedica Reports Third Quarter 2023 Financial Results and Provides Clinical & Corporate UpdatesNovember 8, 2023 | msn.comCalciMedia CEO discloses purchase of 2K sharesNovember 7, 2023 | msn.comCalciMedica chief business officer discloses purchase of about 9k sharesNovember 2, 2023 | finance.yahoo.comCalciMedica Announces Presentation of Initial Data from the CRSPA Study of Auxora at the 65th Annual ASH Meeting & ExpositionSeptember 6, 2023 | finance.yahoo.comCalciMedica Announces Upcoming Presentations and Events in SeptemberAugust 31, 2023 | finance.yahoo.comCalciMedica to Host Acute Pancreatitis Clinical Experts Event on September 21, 2023August 11, 2023 | finance.yahoo.comCalciMedica Reports Second Quarter 2023 Financial Results and Provides Clinical & Corporate UpdatesAugust 9, 2023 | finance.yahoo.comCalciMedica Announces First Patient Enrolled in International Expansion of CARPO Trial of Auxora™ in Acute Pancreatitis (AP)July 21, 2023 | wsj.comCalciMedica Inc.July 13, 2023 | finance.yahoo.comCALC - CalciMedica, Inc.June 27, 2023 | marketbeat.comTrading was temporarily halted for "CALC" at 09:06 AM with a stated reason of "LULD pause."June 20, 2023 | benzinga.comEF Hutton Initiates Coverage On CalciMedica with Buy Rating, Announces Price Target of $17June 14, 2023 | marketbeat.comTrading was temporarily halted for "CALC" at 10:06 AM with a stated reason of "LULD pause."June 14, 2023 | marketbeat.comTrading was temporarily halted for "CALC" at 10:06 AM with a stated reason of "LULD pause."June 14, 2023 | marketbeat.comTrading was temporarily halted for "CALC" at 10:06 AM with a stated reason of "LULD pause."June 12, 2023 | msn.comCalciMedica will be relisted on NasdaqJune 12, 2023 | finance.yahoo.comCalciMedica Announces Relisting on NasdaqJune 6, 2023 | finance.yahoo.comCalciMedica Announces Publication of Preclinical Data in Journal of Clinical Investigation (JCI) Insight Supporting the Development of CRAC Channel Inhibitors for Chronic Pancreatitis (CP)May 23, 2023 | finance.yahoo.comLife Biosciences Expands Team with the Appointment of Ming Yang, Ph.D., as SVP of Research and DevelopmentMay 16, 2023 | morningstar.comCalciMedica Inc Ordinary Shares Get CalciMedica News Delivered to You Automatically Sign up to receive the latest news and ratings for CALC and its competitors with MarketBeat's FREE daily newsletter. Email Address A ‘DeFi Summer’ Projected! (Ad)Top analysts are predicting DeFi coins to see massive gains in the coming months… During this dubbed ‘DeFi Summer…’ A coin that has been called the “DeFi pioneer” is poised to shoot up 3-7x! Just click here to learn how you can access this coin right now. CALC Media Mentions By Week CALC Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CALC News Sentiment▼0.780.55▲Average Medical News Sentiment CALC News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CALC Articles This Week▼111▲CALC Articles Average Week Get CalciMedica News Delivered to You Automatically Sign up to receive the latest news and ratings for CALC and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: AEON Biopharma News Annovis Bio News Immix Biopharma News Checkpoint Therapeutics News Reneo Pharmaceuticals News Celularity News Kezar Life Sciences News Eagle Pharmaceuticals News Aileron Therapeutics News Eledon Pharmaceuticals News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CALC) was last updated on 5/16/2024 by MarketBeat.com Staff From Our PartnersHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportBiden to Drop BOMBSHELL June 13th?Paradigm PressElon to Transform U.S. Economy? Porter & CompanyCharles Payne Demystifies OptionsUnstoppable ProsperityThe most important AI company you've never heard ofManward PressThe #1 Biotech Stock to Watch in 2024 is Attacking Viruses in a Unique WaySmallcaps DailyElon’s New Device is About to Shock the WorldInvestorPlaceGold ManiaStansberry Research Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CalciMedica, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
